{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T16:08:30Z","timestamp":1776096510864,"version":"3.50.1"},"reference-count":26,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"14","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurosurg Case Lessons"],"published-print":{"date-parts":[[2026,4,6]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Clot formation can lead to serious complications associated with endovascular procedures. Cangrelor, a novel intravenous (IV) antiplatelet medication, has been FDA approved for percutaneous coronary intervention. However, the use of cangrelor for the purpose of rescue therapy in neurovascular procedures has not been established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBSERVATIONS<\/jats:title>\n                    <jats:p>At the authors\u2019 institution, 4 patients received IV cangrelor for emergency thrombolysis during cerebral aneurysm embolization. In 3 cases, thrombus resolution was observed within minutes of cangrelor administration, restoring normal flow. In 1 case, cangrelor facilitated partial thrombolysis in conjuction with mechanical thrombectomy. No patient experienced an ischemic stroke or hemorrhagic complication. All patients were discharged home at their neurological baseline. Follow-up demonstrated no recurrent thrombosis or aneurysm recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LESSONS<\/jats:title>\n                    <jats:p>In this limited series, cangrelor was found to be a safe and effective IV platelet inhibitor with emergency thrombolysis capability after cerebral aneurysm embolization. Cangrelor is an attractive rescue agent due to its rapid onset, reversible P2Y12 inhibition, and extremely short half-life (on\/off effect).<\/jats:p>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/thejns.org\/doi\/10.3171\/CASE25930\">https:\/\/thejns.org\/doi\/10.3171\/CASE25930<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/case25930","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T10:04:33Z","timestamp":1775642673000},"source":"Crossref","is-referenced-by-count":0,"title":["Intravenous cangrelor as rescue therapy for acute thrombosis in neuroendovascular procedures: illustrative cases"],"prefix":"10.3171","volume":"11","author":[{"given":"Mehlika Esra","family":"Sahin","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Duke University, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4916-788X","authenticated-orcid":true,"given":"Amy T.","family":"Fulton","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Duke University, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunishka","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Duke University, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenan","family":"Alkhalili","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Duke University, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1710-2746","authenticated-orcid":true,"given":"Erik F.","family":"Hauck","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Duke University, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1754","reference":[{"issue":"12","key":"bib1","series-title":"Drugs","first-page":"1425","article-title":"Cangrelor: a review in percutaneous coronary intervention","volume":"75","author":"Keating","year":"2015","unstructured":"Keating GM.Cangrelor: a review in percutaneous coronary intervention. Drugs. 2015;75(12):1425-1434. doi:10.1007\/s40265-015-0445-3"},{"key":"bib2","series-title":"Pharmacol Ther","first-page":"102","article-title":"Current status of data on cangrelor","volume":"159","author":"Qamar","year":"2016","unstructured":"Qamar ABhatt DL.Current status of data on cangrelor. Pharmacol Ther. 2016;159:102-109. doi:10.1016\/j.pharmthera.2016.01.004"},{"issue":"13","key":"bib3","series-title":"Circulation","first-page":"e771","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"151","author":"Rao","year":"2025","unstructured":"Rao SVO\u2019Donoghue MLRuel M2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation. 2025;151(13):e771-e862. doi:10.1161\/CIR.0000000000001309"},{"issue":"4","key":"bib4","series-title":"J Neurointerv Surg","first-page":"347","article-title":"Safety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology: preliminary experience in a single-center pilot study","volume":"11","author":"Aguilar-Salinas","year":"2019","unstructured":"Aguilar-Salinas PAgnoletto GJBrasiliense LBCSafety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology: preliminary experience in a single-center pilot study. J Neurointerv Surg. 2019;11(4):347-351. doi:10.1136\/neurintsurg-2018-014396"},{"issue":"1","key":"bib5","series-title":"J Neurointerv Surg","first-page":"88","article-title":"Efficacy and safety of low dose intravenous cangrelor in a consecutive cohort of patients undergoing neuroendovascular procedures","volume":"16","author":"Cagnazzo","year":"2023","unstructured":"Cagnazzo FRadu RADerraz IEfficacy and safety of low dose intravenous cangrelor in a consecutive cohort of patients undergoing neuroendovascular procedures. J Neurointerv Surg. 2023;16(1):88-93. doi:10.1136\/jnis-2023-020094"},{"issue":"6","key":"bib6","series-title":"Neuroradiology","first-page":"1567","article-title":"Cangrelor, a newer P2Y12 inhibitor, in neuro-interventional procedures: a systematic review and updated meta-analysis","volume":"67","author":"Gon\u00e7alves","year":"2025","unstructured":"Gon\u00e7alves ORSantos ABHong ACangrelor, a newer P2Y12 inhibitor, in neuro-interventional procedures: a systematic review and updated meta-analysis. Neuroradiology. 2025;67(6):1567-1578. doi:10.1007\/s00234-025-03573-6"},{"issue":"6","key":"bib7","series-title":"Circulation","first-page":"e129","article-title":"CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association","volume":"150","author":"Pereira","year":"2024","unstructured":"Pereira NLCresci SAngiolillo DJCYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association. Circulation. 2024;150(6):e129-e150. doi:10.1161\/CIR.0000000000001257"},{"issue":"6","key":"bib8","series-title":"Clin Ther","first-page":"1199","article-title":"Influence of CYP450 enzymes, CES1, PON1, ABCB1, and P2RY12 polymorphisms on clopidogrel response in patients subjected to a percutaneous neurointervention","volume":"41","author":"Saiz-Rodr\u00edguez","year":"2019","unstructured":"Saiz-Rodr\u00edguez MBelmonte CCaniego JLInfluence of CYP450 enzymes, CES1, PON1, ABCB1, and P2RY12 polymorphisms on clopidogrel response in patients subjected to a percutaneous neurointervention. Clin Ther. 2019;41(6):1199-1212.e2. doi:10.1016\/j.clinthera.2019.04.037"},{"issue":"11","key":"bib9","series-title":"Expert Opin Drug Metab Toxicol","first-page":"1079","article-title":"Clopidogrel drug interactions: a review of the evidence and clinical implications","volume":"16","author":"Lee","year":"2020","unstructured":"Lee CHFranchi FAngiolillo DJ.Clopidogrel drug interactions: a review of the evidence and clinical implications. Expert Opin Drug Metab Toxicol. 2020;16(11):1079-1096. doi:10.1080\/17425255.2020.1814254"},{"issue":"3","key":"bib10","series-title":"Neurosurgery","first-page":"268","article-title":"Glycoprotein IIb\/IIIa inhibitors in prevention and rescue treatment of thromboembolic complications during endovascular embolization of intracranial aneurysms","volume":"82","author":"Dornbos","year":"2018","unstructured":"Dornbos DIIIKatz JSYoussef PPowers CJNimjee SM.Glycoprotein IIb\/IIIa inhibitors in prevention and rescue treatment of thromboembolic complications during endovascular embolization of intracranial aneurysms. Neurosurgery. 2018;82(3):268-277. doi:10.1093\/neuros\/nyx170"},{"key":"bib11","series-title":"Front Neurol","first-page":"1304599","article-title":"Intravenous cangrelor use for neuroendovascular procedures: a two-center experience and updated systematic review","volume":"14","author":"Desai","year":"2023","unstructured":"Desai HAl-Salihi MMMorsi RZIntravenous cangrelor use for neuroendovascular procedures: a two-center experience and updated systematic review. Front Neurol. 2023;14:1304599. doi:10.3389\/fneur.2023.1304599"},{"issue":"1","key":"bib12","series-title":"Coron Artery Dis","first-page":"65","article-title":"Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists","volume":"27","author":"Schneider","year":"2016","unstructured":"Schneider DJ.Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists. Coron Artery Dis. 2016;27(1):65-69. doi:10.1097\/MCA.0000000000000311"},{"issue":"2","key":"bib13","series-title":"Chest","first-page":"e120S","article-title":"New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Weitz","year":"2012","unstructured":"Weitz JIEikelboom JWSamama MM.New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2)(suppl):e120S-e151S. doi:10.1378\/chest.11-2294"},{"issue":"12","key":"bib1","series-title":"Drugs","first-page":"1425","article-title":"Cangrelor: a review in percutaneous coronary intervention","volume":"75","author":"Keating","year":"2015","unstructured":"Keating GM.Cangrelor: a review in percutaneous coronary intervention. Drugs. 2015;75(12):1425-1434. doi:10.1007\/s40265-015-0445-3"},{"key":"bib2","series-title":"Pharmacol Ther","first-page":"102","article-title":"Current status of data on cangrelor","volume":"159","author":"Qamar","year":"2016","unstructured":"Qamar ABhatt DL.Current status of data on cangrelor. Pharmacol Ther. 2016;159:102-109. doi:10.1016\/j.pharmthera.2016.01.004"},{"issue":"13","key":"bib3","series-title":"Circulation","first-page":"e771","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"151","author":"Rao","year":"2025","unstructured":"Rao SVO\u2019Donoghue MLRuel M2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation. 2025;151(13):e771-e862. doi:10.1161\/CIR.0000000000001309"},{"issue":"4","key":"bib4","series-title":"J Neurointerv Surg","first-page":"347","article-title":"Safety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology: preliminary experience in a single-center pilot study","volume":"11","author":"Aguilar-Salinas","year":"2019","unstructured":"Aguilar-Salinas PAgnoletto GJBrasiliense LBCSafety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology: preliminary experience in a single-center pilot study. J Neurointerv Surg. 2019;11(4):347-351. doi:10.1136\/neurintsurg-2018-014396"},{"issue":"1","key":"bib5","series-title":"J Neurointerv Surg","first-page":"88","article-title":"Efficacy and safety of low dose intravenous cangrelor in a consecutive cohort of patients undergoing neuroendovascular procedures","volume":"16","author":"Cagnazzo","year":"2023","unstructured":"Cagnazzo FRadu RADerraz IEfficacy and safety of low dose intravenous cangrelor in a consecutive cohort of patients undergoing neuroendovascular procedures. J Neurointerv Surg. 2023;16(1):88-93. doi:10.1136\/jnis-2023-020094"},{"issue":"6","key":"bib6","series-title":"Neuroradiology","first-page":"1567","article-title":"Cangrelor, a newer P2Y12 inhibitor, in neuro-interventional procedures: a systematic review and updated meta-analysis","volume":"67","author":"Gon\u00e7alves","year":"2025","unstructured":"Gon\u00e7alves ORSantos ABHong ACangrelor, a newer P2Y12 inhibitor, in neuro-interventional procedures: a systematic review and updated meta-analysis. Neuroradiology. 2025;67(6):1567-1578. doi:10.1007\/s00234-025-03573-6"},{"issue":"6","key":"bib7","series-title":"Circulation","first-page":"e129","article-title":"CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association","volume":"150","author":"Pereira","year":"2024","unstructured":"Pereira NLCresci SAngiolillo DJCYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American Heart Association. Circulation. 2024;150(6):e129-e150. doi:10.1161\/CIR.0000000000001257"},{"issue":"6","key":"bib8","series-title":"Clin Ther","first-page":"1199","article-title":"Influence of CYP450 enzymes, CES1, PON1, ABCB1, and P2RY12 polymorphisms on clopidogrel response in patients subjected to a percutaneous neurointervention","volume":"41","author":"Saiz-Rodr\u00edguez","year":"2019","unstructured":"Saiz-Rodr\u00edguez MBelmonte CCaniego JLInfluence of CYP450 enzymes, CES1, PON1, ABCB1, and P2RY12 polymorphisms on clopidogrel response in patients subjected to a percutaneous neurointervention. Clin Ther. 2019;41(6):1199-1212.e2. doi:10.1016\/j.clinthera.2019.04.037"},{"issue":"11","key":"bib9","series-title":"Expert Opin Drug Metab Toxicol","first-page":"1079","article-title":"Clopidogrel drug interactions: a review of the evidence and clinical implications","volume":"16","author":"Lee","year":"2020","unstructured":"Lee CHFranchi FAngiolillo DJ.Clopidogrel drug interactions: a review of the evidence and clinical implications. Expert Opin Drug Metab Toxicol. 2020;16(11):1079-1096. doi:10.1080\/17425255.2020.1814254"},{"issue":"3","key":"bib10","series-title":"Neurosurgery","first-page":"268","article-title":"Glycoprotein IIb\/IIIa inhibitors in prevention and rescue treatment of thromboembolic complications during endovascular embolization of intracranial aneurysms","volume":"82","author":"Dornbos","year":"2018","unstructured":"Dornbos DIIIKatz JSYoussef PPowers CJNimjee SM.Glycoprotein IIb\/IIIa inhibitors in prevention and rescue treatment of thromboembolic complications during endovascular embolization of intracranial aneurysms. Neurosurgery. 2018;82(3):268-277. doi:10.1093\/neuros\/nyx170"},{"key":"bib11","series-title":"Front Neurol","first-page":"1304599","article-title":"Intravenous cangrelor use for neuroendovascular procedures: a two-center experience and updated systematic review","volume":"14","author":"Desai","year":"2023","unstructured":"Desai HAl-Salihi MMMorsi RZIntravenous cangrelor use for neuroendovascular procedures: a two-center experience and updated systematic review. Front Neurol. 2023;14:1304599. doi:10.3389\/fneur.2023.1304599"},{"issue":"1","key":"bib12","series-title":"Coron Artery Dis","first-page":"65","article-title":"Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists","volume":"27","author":"Schneider","year":"2016","unstructured":"Schneider DJ.Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists. Coron Artery Dis. 2016;27(1):65-69. doi:10.1097\/MCA.0000000000000311"},{"issue":"2","key":"bib13","series-title":"Chest","first-page":"e120S","article-title":"New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Weitz","year":"2012","unstructured":"Weitz JIEikelboom JWSamama MM.New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2)(suppl):e120S-e151S. doi:10.1378\/chest.11-2294"}],"container-title":["Journal of Neurosurgery: Case Lessons"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg-case-lessons\/11\/14\/article-CASE25930.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg-case-lessons\/11\/14\/article-CASE25930.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg-case-lessons\/11\/14\/article-CASE25930.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T15:27:35Z","timestamp":1776094055000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg-case-lessons\/11\/14\/article-CASE25930.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":26,"journal-issue":{"issue":"14"},"URL":"https:\/\/doi.org\/10.3171\/case25930","relation":{},"ISSN":["2694-1902"],"issn-type":[{"value":"2694-1902","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]}}}